Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

作者：Yi-Long Lung Cancer Wu, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jin‐Ji Yang, Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazieres, Lye Mun Tho, Hidetoshi Hayashi, Nguyen Viet Nhung, Puey Ling Chia, Filippo de Marinis, Jo Raskin, Qinghua Zhou, Giovanna Finocchiaro, Anh Tuan Le, Jialei Wang, Christophe Dooms, Terufumi Kato, Ernest Nadal, How Soon Hin, Egbert Frederik Smit, Martin Wermke, Daniel S.W. Tan, Masahiro Morise, Aurora O’Brate, Svenja Adrian, Boris Mirko Pfeiffer, Christopher Stroh, Dilafruz Juraeva, Rainer Strotmann, Kosalaram Goteti, Karin Berghoff, Barbara Ellers‐Lenz, Niki Karachaliou, Xiuning Le, Tae Min Kim · 发表于：The Lancet Oncology · 年份：2024 · DOI：10.1016/s1470-2045(24)00270-5 · 被引用次数：105 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Lung Cancer Research Studies